JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
QUICK SEARCH:   [advanced]


     

J Am Coll Cardiol, 2006; 48:270-275, doi:10.1016/j.jacc.2006.03.039 (Published online 22 June 2006).
© 2006 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liistro, F.
Right arrow Articles by Bolognese, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liistro, F.
Right arrow Articles by Bolognese, L.

Effectiveness and Safety of Sirolimus Stent Implantation for Coronary In-Stent Restenosis

The TRUE (Tuscany Registry of Sirolimus for Unselected In-Stent Restenosis) Registry

Francesco Liistro, MD*,*, Massimo Fineschi, MD{dagger}, Paolo Angioli, MD*, Giuseppe Sinicropi, MD{dagger}, Giovanni Falsini, MD*, Tommaso Gori, MD{dagger}, Kenneth Ducci, MD*, Achille Bravi, MD{dagger} and Leonardo Bolognese, MD*

* Cardiovascular Departments of San Donato Hospital, Arezzo, Italy
{dagger} Le Scotte Hospital, Siena, Italy.


Figure 1
View larger version (12K):

[in a new window]
  		Figure 1 Cumulative distribution of late loss at angiographic follow-up. Restenosis and ischemia-driven target lesion revascularization (TLR) is reported corresponding to the respective late loss value for each lesion.

 

Figure 2
View larger version (14K):

[in a new window]
  		Figure 2 (A) Kaplan-Meier analysis for 9-month major adverse cardiac event (MACE)-free survivals in diabetic and nondiabetic patients. (B) Kaplan-Meier analysis for survivals free from 9-month ischemia-driven target lesion revascularization (TLR) in diabetic and nondiabetic patients.

 

Figure 3
View larger version (13K):

[in a new window]
  		Figure 3 (A) Kaplan-Meier analysis for 9-month major adverse cardiac event (MACE)-free survivals in patients with non–ST-segment elevation acute coronary syndrome (NSTEACS) and in those with stable angina. (B) Kaplan-Meier analysis for survivals free from 9-month ischemia-driven target lesion revascularization (TLR) in NSTEACS patients and in those with stable angina.

 




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2006 by the American College of Cardiology Foundation.